News Archive

14 January 2016

Merck Animal Health Highlights Commitment to Poultry Industry at 2016 International Production & Processing Expo

                                                                                                                            

·        Third Annual Culinary Tour of Nations Luncheon

·        Scientific Data Presentations Highlighting Vaccination Benefits

·        Expert Conversations Via Step Up to Solutions


MADISON, N.J., January 14, 2016 – Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced its renewed commitment to the poultry industry with several programs at the 2016 International Production & Processing Expo (IPPE), which are aimed at helping customers learn more about poultry production across the world and troubleshoot issues in their operations. The IPPE will be held in Atlanta, Georgia from January 26-28, 2016.

At the Expo, the company will host the third annual Culinary Tour of Nations luncheon, where attendees will have the opportunity to enjoy poultry dishes from different continents while networking with poultry production professionals from around the world. The invitation-only luncheon will be held on January 27 from 12:00-1:30 p.m. ET in the Georgia World Congress Center.

A limited number of attendees will be invited to Step Up to Solutions at the top of Merck Animal Health’s two-story booth (#A2619), where they can have one-on-one consultations with experts on issues such as poultry economics, market access, respiratory health, in-ovo and early nutrition, water quality and intestinal health. At the Expo, Merck Animal Health will also introduce STARTS HERE, a new informational program to support poultry producers.

“At Merck Animal Health, we are committed to providing our customers with the knowledge and solutions they need to improve their businesses,” said Delair Bolis, Global Poultry Business Unit Head, Merck Animal Health. “We are pleased to offer these educational events at the Expo where these important conversations will continue to support our customers by ensuring all involved have the right information to make sound business decisions.”

Attendees who are interested in attending the Culinary Tour of Nations event or Step Up to Solutions should contact their local Merck Animal Health sales representative or visit the Merck Animal Health booth at the Expo (Booth #A2619).

Merck Animal Health will also present several posters during a reception on Monday, January 25th at 4:00 PM in room B313 at the Expo, including:

  • Variant Infectious Bronchitis Strains in the Middle East
    Husam Bakri, Merck Animal Health Scientific Affairs
    Poster #235
  • Changing IBV Vaccination Program Can Improve Farm Profitability
    Corrado Longoni, Merck Animal Health Scientific Affairs
    Poster #234
  • Isolation of Clostridium perfringensfrom Poultry in Antibiotic-Free Commercial Farms
    Fernando Vargas, Global Technical Director, Merck Animal Health
    Poster #227
  • Resistance Profile and Genetic Characterization of Clostridium perfringens in Poultry from Brazilian Antibiotic Free Commercial Farms
    Fernando Vargas, Global Technical Director, Merck Animal Health
    Poster #228
  • Oral presentations include:

    • Evaluation of the synergistic effect of the live attenuated bursal disease vaccine 89/03 and a recombinant HVT-IBD against early infectious bursal disease challenge in commercial broilers

    Ivan Alvarado, Merck Animal Health Scientific Affairs
    January 26th at 7:30 AM in room B312

    • Sanitization of a Marek’s vaccination device: Impact on vaccine viability

    Alexandra Reilley, Merck Animal Health Scientific Affairs
    January 26th at 10:30 Am in room B314

    For more information about the International Production & Processing Expo, visit http://www.ippexpo.org/.

    About Merck Animal Health
    Today's Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck.Through its commitment to the Science of Healthier Animals™ , Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions
    and services. Merck Animal Health is dedicated to preserving and improving the health, well-
    being and performance of animals. It invests extensively in dynamic and comprehensive R&D
    resources and a modern, global supply chain. Merck Animal Health is present in more than 50
    countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn and Twitter.

    Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
    This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

    Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

    The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).